Hairy Cell Leukemia Foundation Annual Conference

Robert J. Kreitman, MD, discusses the role of minimal residual disease (MRD) status in hairy cell leukemia, how to effectively test for MRD, and how the combination of moxetumomab pasudotox and rituximab could alter the treatment landscape.

The standard of care for the frontline treatment of patients with hairy cell leukemia has been purine nucleoside analogs, including pentostatin and cladribine; however, investigators are challenging this treatment in a phase II clinical trial with a targeted therapy that may provide similar benefit with fewer toxicities.

Agnieszka Janus, MD, PhD, shares perspective on three cases of patients with HCL who were given vemurafenib after having progressed on multiple lines of treatment.

Kerry Rogers, MD, discusses the potential of ibrutinib (Imbruvica) in hairy cell leukemia, emerging treatment options such as moxetumomab pasudotox (Lumoxiti), and next steps and challenges in the field.

Robert J. Kreitman, MD, discusses the association between minimal residual disease-negativity and complete remission durations in patients with hairy cell leukemia treated with moxetumomab pasudotox.

Justin Taylor, MD, discusses the design of an ongoing phase II clinical trial evaluating the combination of frontline vemurafenib plus obinutuzumab in patients with hairy cell leukemia.

James Blachly, MD, discusses the role of circulating tumor DNA as a biomarker for patients with hairy cell leukemia.

Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.

Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.

Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.